BPC-157: What 30 Years of Preclinical Evidence Actually Shows

Editorial disclaimer: EOS Research summarizes published research for educational purposes. BPC-157 is not approved by the FDA or other major regulatory authorities for human therapeutic use. The FDA has specifically identified potential immunogenicity, peptide impurities, API-characterization problems, and insufficient human safety information as concerns associated with this compound. This brief is not medical advice and does not constitute a recommendation to use any substance. Always consult a licensed healthcare provider before starting any new protocol.

BPC-157 is often discussed online as if its therapeutic value were settled. It is not. What we have is a long, consistent body of animal research and a striking absence of high-quality human data. This brief asks the question that matters: what has actually been demonstrated, in which models, and with what confidence — and what remains unknown?

The question

What does the published literature actually establish about BPC-157, and where does popular interpretation move beyond the available evidence? The distinction between preclinical signal and clinical validation is the center of this story — not a footnote.

What the evidence says

BPC-157 — short for Body Protection Compound-157 — is a pentadecapeptide (15 amino acids) originally isolated from human gastric juice. It was identified as a stable fragment of a larger protein involved in protecting and healing the gastrointestinal lining.¹

Across nearly three decades of preclinical research, BPC-157 has demonstrated what researchers call pleiotropic effects — meaning it appears to influence healing across multiple tissue types simultaneously: tendon, ligament, muscle, bone, nerve, blood vessel, and the gastrointestinal tract.^2,3 Unlike many growth factors that are tissue-specific or carrier-dependent, BPC-157 has shown consistent healing effects alone, across multiple injury models, and through multiple routes of administration — oral, intraperitoneal, topical, and local injection.⁴

The body of evidence is broad but it comes with an important caveat: the overwhelming majority of studies have been conducted in rodent models. Human data is limited to one small retrospective study and one registered Phase I study with no posted results or identified publication. This gap between preclinical promise and clinical validation is the central tension in any serious discussion of BPC-157 — and it is why the compound sits at the frontier of what biohackers explore rather than inside standard medical practice.

Mechanisms

The precise mechanisms are still being mapped, but several pathways have been identified across the literature:

Angiogenesis via VEGFR2. Animal studies report that BPC-157 activates the VEGF receptor 2 (VEGFR2) pathway, driving new blood vessel formation in tested models.⁵ This pro-angiogenic effect has been described as broadly similar in direction to endogenous growth factors like VEGF, FGF, and EGF, though its wider applicability across tissue types is based on preclinical observations.⁴

Growth hormone receptor expression. A 2025 systematic review notes that BPC-157 enhances growth hormone receptor expression, which may partly explain its effects on muscle, tendon, and bone healing.⁶

Nitric oxide (NO) system modulation. Animal studies describe BPC-157 interacting with NO signaling in context-dependent ways — counteracting both NO overproduction and NO blockade depending on physiological state. This context-dependent modulation has been reported by the Sikiric group as potentially distinct from single-pathway agents.^7,8

Inflammatory cytokine reduction. Preclinical models consistently show reductions in TNF-α, IL-1β, and other inflammatory markers following BPC-157 administration. The mechanism by which this occurs is not fully established, but animal studies report cytokine modulation consistent with inflammatory-phase resolution.⁹

Cytoprotection. The Sikiric research group at the University of Zagreb, which has contributed the largest share of BPC-157 literature, uses the term "cytoprotection" to describe BPC-157's core action: helping cells survive and maintain function under conditions that would otherwise cause damage — whether chemical (NSAIDs, alcohol), mechanical (surgical anastomosis), ischemic (stroke models), or neurological (dopamine and serotonin system disruption).

Pharmacokinetics. In animal models and one systematic review, BPC-157 is reported to be metabolized in the liver, have a half-life of less than 30 minutes, and be cleared by the kidneys.⁶ Human pharmacokinetic data have not been published; whether these values translate to humans is unknown.

Exposure regimens reported in research

The ranges below are drawn from published research, not clinical prescribing guidelines. BPC-157 has no approved human dosing schedule. No dosing recommendations are made here.

Research doses:

• Preclinical (rodent): 10 µg/kg is the widely used effective dose across injury models. Acute and chronic administration both show effects.
• Phase I trial (NCT02637284, 2015): A 42-participant Phase I study was registered for oral BPC-157 tablets at 1, 3, and 6 mg single doses, plus 3 mg three times daily for two weeks in healthy volunteers. No results are posted in the registry and our search identified no associated publication. A registration is not evidence that enrollment or completion occurred.
• Preclinical toxicology (Xu et al., 2020): Comprehensive toxicology across mice, rats, rabbits, and dogs found no serious toxicity, no genotoxicity, and no embryo-fetal toxicity under the studied conditions. The tested animal models did not identify certain toxicities; these findings do not establish human safety, injectable-product safety, or long-term safety.¹¹
• Lee & Padgett (2021): A small, retrospective, uncontrolled case series of intra-articular BPC-157 injection for knee pain in 16 patients. Eleven of twelve patients receiving BPC-157 alone reported improvement (subject to major selection, measurement, and placebo-effect limitations).¹⁰

What we don't know

This section is mandatory in every EOS Research brief, and for BPC-157 it is unusually important. The honest answer is that we know less than the volume of online discussion suggests.

No published human efficacy trial. A 42-participant Phase I study was registered in 2015 but no results were posted and our search identified no associated publication. The Lee & Padgett study is a small, retrospective, uncontrolled case series. There is no randomized controlled trial demonstrating clinical efficacy in humans for any indication.

No long-term safety data in humans. Animal toxicology (Xu et al., 2020) showed no identified toxicities under studied conditions, but this cannot substitute for human chronic-exposure data. The compound has been in research use for nearly three decades without producing such data — a fact that should give pause before any extended use.

Unknown drug interactions. BPC-157 modulates nitric oxide signaling, growth hormone receptor expression, and multiple cytokine pathways. The interaction profile with pharmaceuticals acting on these systems (SSRIs, NSAIDs, growth hormone, PDE5 inhibitors, blood pressure medications) is essentially unstudied in humans.

Product quality is a real variable. BPC-157 is sold for "research use only," and purity varies across vendors. Third-party testing is uneven. The dose on the label may not match the dose in the vial. Until pharmaceutical-grade material becomes available, this is a confound in every community report.

Optimal dose-response is unknown. Animal research has not identified a clear toxicity threshold under studied conditions, but human dose-response data simply does not exist. No dosing recommendations can be derived from the available evidence.

WADA status. BPC-157 is prohibited under the World Anti-Doping Agency's S0 (non-approved substances) category. Athletes subject to anti-doping rules should verify current status before any use.

Research-group concentration. A plurality of the studies cited in this brief originate from the Sikiric research network at the University of Zagreb. This concentration means the published literature may not represent independent replication across unrelated laboratories.

Absence of evidence is not proof of no effect — but it is a limit on confident claims.

Takeaway

BPC-157 has a longer and more consistent preclinical track record than most compounds that biohackers experiment with. The breadth of effects across multiple injury models and the absence of identified toxicity under the conditions tested in several animal studies are noteworthy. The consistency of findings is partly attributable to a single research group (the Sikiric network at the University of Zagreb contributed a plurality of the studies reviewed) — a concentration that should be weighed when assessing independence.

What we have is a body of animal evidence that is unusually broad in scope. What we do not have is clinical evidence that BPC-157 works in humans at any dose, for any condition, with any safety profile over any meaningful time horizon.

The reported preclinical signals are extensive. The confident human claims are unsupported. Knowing which is which is the entire job.

Methodology notes

Search strategy. PubMed and CrossRef were searched for "BPC-157" OR "body protection compound-157" OR "pentadecapeptide BPC" in title, abstract, and keyword fields. Date range: 1993 (first characterization) through June 2026. The Sikiric research group bibliography at the University of Zagreb was cross-referenced for completeness. ClinicalTrials.gov was searched for registered trials using "BPC-157" as the intervention.

Inclusion criteria. Peer-reviewed primary research articles, systematic reviews, and registered clinical trials in English. Conference abstracts, preprints, and non-English content without translation were excluded.

Results. A total of 118 records were screened (search conducted 11 July 2026). Thirty-nine papers were reviewed in full. Twelve publications — including primary studies and evidence reviews — were selected for detailed citation, plus one clinical-trial registry record.

Evidence grading. Sources are cited with their study design implicit in the reference context. Preclinical, observational, and clinical evidence are clearly distinguished in the body text. The absence of randomized controlled trials is noted explicitly rather than treated as a gap to be filled by weaker evidence.

Editorial process. Nox (AI research operator) conducted the literature review, drafted the brief, and structured the evidence synthesis. Monty (founder, EOS Commons) reviewed the brief for accuracy, framing, and separation of preclinical signal from human claim. Nothing is auto-published.

Conflicts of interest. No commercial relationships with BPC-157 manufacturers, vendors, or distributors. No financial interest in any compound discussed. The author's interest is accurate synthesis of the available literature — not advocacy for or against any intervention.

Update policy. This brief will be revised as new clinical evidence becomes available. The next planned review is July 2027, or earlier if a human RCT is published. Substantive changes will be noted in a version log appended to the reference section.

References

1. Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87(5):313-327. PMID: 8298609.
2. Seiwerth S, Milavic M, Vukojevic J, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021;12:627533. PMID: 34267654.
3. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. PMID: 30915550.
4. Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and Standard Angiogenic Growth Factors. Curr Pharm Des. 2018;24(18):1972-1989. PMID: 29998800.
5. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95:323-333. PMID: 27847966.
6. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):15563316251355551. PMID: 40756949.
7. Sikiric P, Boban Blagaic A, Strbe S, et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel). 2024;17(4):461. PMID: 38675421.
8. Vukojevic J, Milavić M, Perović D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487. PMID: 34380875.
9. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. PMID: 40005999.
10. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID: 34324435.
11. Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. PMID: 32334036.
12. Staresinic M, Japjec M, Vranes H, et al. Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. Biomedicines. 2022;10(12):3221. PMID: 36551977.
13. ClinicalTrials.gov. PCO-02 — Safety and Pharmacokinetics Trial. Identifier: NCT02637284. 2015. No results posted; no associated publication identified as of 11 July 2026.

Discuss in EOS Commons. The companion snippet is posted in the #longevity-science channel for member discussion. Questions and pushback from the community feed back into revisions of this brief.